Literature DB >> 2947256

Suppression of the hypo- and hyperthermic responses to 5-HT agonists following the repeated administration of monoamine oxidase inhibitors.

G A Gudelsky, J I Koenig, H Jackman, H Y Meltzer.   

Abstract

Hypo- and hyperthermic responses resulting from the activation of putative 5-HT1A and 5-HT2 receptors, respectively, were examined after the chronic treatment of rats with monoamine oxidase inhibitors. The treatment of rats for 4 or 7 days with nialamide (40 mg/kg, twice daily) resulted in a suppression of the hypothermic effect of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT, 0.05-0.25 mg/kg, SC). The decrease in body temperature elicited by a low dose of 5-methoxy-N, N-dimethyltryptamine (5MeODMT, 1 mg/kg) also was diminished in rats treated chronically with nialamide. The administration of a high dose of 5MeODMT (5 mg/kg) resulted in a hyperthermic response, which was also attenuated after the repeated administration of nialamide. The repeated administration of clorgyline (a selective inhibitor of type A MAO) or deprenyl (a selective inhibitor of type B MAO) failed to alter the hypothermic effect of 8-OH-DPAT. However, in animals treated chronically with both clorgyline and deprenyl, a suppressed response to 8-OH-DPAT was observed. In view of the concept that the hypo- and hyperthermic responses to 5-HT agonists are mediated by 5-HT1A and 5-HT2 receptor subtypes, respectively, it is concluded that the responsiveness of these 5-HT receptor subtypes involved in thermoregulatory responses is decreased following chronic treatment of rats with monoamine oxidase inhibitors. It appears that inhibition of both type A and B MAO is necessary for this desensitization process.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2947256     DOI: 10.1007/bf00179199

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  21 in total

1.  Decrease in [3H]-serotonin binding in rat brain produced by the repeated administration of either monoamine oxidase inhibitors or centrally acting serotonin agonists.

Authors:  D D Savage; J Mendels; A Frazer
Journal:  Neuropharmacology       Date:  1980-11       Impact factor: 5.250

2.  Comparison of platelet count and platelet protein methods for determination of platelet MAO activity.

Authors:  H Jackman; R Arora; H Y Meltzer
Journal:  Clin Chim Acta       Date:  1979-08-15       Impact factor: 3.786

3.  A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors.

Authors:  G M Goodwin; A R Green
Journal:  Br J Pharmacol       Date:  1985-03       Impact factor: 8.739

4.  Evidence that 5-HT agonist-induced rotational behaviour in the rat is mediated via 5-HT1 receptors.

Authors:  T P Blackburn; J D Kemp; D A Martin; B Cox
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

5.  Amitriptyline and femoxetine, but not clomipramine or citalopram, antagonize hyperthermia induced by directly acting 5-hydroxytryptamine-like drugs in heat adapted rats.

Authors:  L Pawłowski
Journal:  J Pharm Pharmacol       Date:  1984-03       Impact factor: 3.765

6.  5-Hydroxytryptamine (5-HT)-dependent myoclonus in guinea pigs is induced through brainstem 5-HT-1 receptors.

Authors:  G Luscombe; P Jenner; C D Marsden
Journal:  Neurosci Lett       Date:  1984-02-24       Impact factor: 3.046

7.  Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat.

Authors:  I Lucki; M S Nobler; A Frazer
Journal:  J Pharmacol Exp Ther       Date:  1984-01       Impact factor: 4.030

8.  The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat.

Authors:  M D Tricklebank; C Forler; J R Fozard
Journal:  Eur J Pharmacol       Date:  1984-11-13       Impact factor: 4.432

9.  Monoamine oxidase inhibitors and serotonin uptake inhibitors: differential effects on [3H]serotonin binding sites in rat brain.

Authors:  D D Savage; J Mendels; A Frazer
Journal:  J Pharmacol Exp Ther       Date:  1980-02       Impact factor: 4.030

10.  Altered responses to serotonergic agents in Fawn-Hooded rats.

Authors:  G A Gudelsky; J I Koenig; H Y Meltzer
Journal:  Pharmacol Biochem Behav       Date:  1985-03       Impact factor: 3.533

View more
  7 in total

1.  Changes in auditory evoked responses and in the inhibitory action of 5-hydroxytryptophan following chronic treatment with imipramine in the rat.

Authors:  M J Rowan; J J O'Connor; R Anwyl
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

2.  Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder.

Authors:  K P Lesch; A Hoh; H M Schulte; M Osterheider; T Müller
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.

Authors:  Adam L Halberstadt
Journal:  Pharmacol Biochem Behav       Date:  2016-01-15       Impact factor: 3.533

Review 4.  Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.

Authors:  Hong-Wu Shen; Xi-Ling Jiang; Jerrold C Winter; Ai-Ming Yu
Journal:  Curr Drug Metab       Date:  2010-10       Impact factor: 3.731

Review 5.  Indolealkylamines: biotransformations and potential drug-drug interactions.

Authors:  Ai-Ming Yu
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

6.  Effects of chronic treatment with valproate on serotonin-1A receptor binding and function.

Authors:  L Khaitan; J R Calabrese; C A Stockmeier
Journal:  Psychopharmacology (Berl)       Date:  1994-01       Impact factor: 4.530

Review 7.  A narrative synthesis of research with 5-MeO-DMT.

Authors:  Anna O Ermakova; Fiona Dunbar; James Rucker; Matthew W Johnson
Journal:  J Psychopharmacol       Date:  2021-10-19       Impact factor: 4.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.